Benefits
- Postprandial glucose control — reduces postprandial glucose excursions by 3–5 mmol/L when added to insulin therapystrong
- HbA1c reduction — additional 0.3–0.6% HbA1c lowering on top of optimized insulin regimensstrong
- Weight loss — promotes 1–2 kg weight loss through satiety enhancement, counteracting insulin-associated weight gainstrong
- Glucagon suppression — reduces inappropriate postprandial glucagon secretion, a major contributor to hyperglycemiastrong
- Insulin dose reduction — allows 30–50% reduction in prandial insulin doses while improving glucose controlmoderate
Dosage Protocols
| Route | Dosage Range | Frequency | Notes |
|---|---|---|---|
| Subcutaneous injection (Type 2 diabetes) | 60–120 mcg | Before major meals (2–3× daily) | Initiate at 60 mcg before meals. Increase to 120 mcg if tolerated after 3–7 days. Reduce prandial insulin dose by 50% at initiation to prevent hypoglycemia. |
| Subcutaneous injection (Type 1 diabetes) | 15–60 mcg | Before major meals (2–3× daily) | Initiate at 15 mcg, titrate upward in 15 mcg increments every 3+ days as tolerated to 30 or 60 mcg. Reduce prandial insulin by 50% at initiation. |
Medical disclaimer
Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.
Side Effects
- Nausea — most common side effect (30–50% initially), typically resolving over 2–4 weeks with dose titrationcommon
- Severe hypoglycemia — risk increases when combined with insulin; prandial insulin dose must be reduced by 50% when initiating pramlintideserious
- Anorexia — reduced appetite reported in 10–15% of patients; generally considered a therapeutic effectcommon
- Injection-site reactions — mild redness or swelling at injection sitecommon
- Headache — reported in 5–13% of patients during clinical trialscommon
Explore Next
Related peptides
Tools
- Peptide Dosage & Reconstitution CalculatorThree calculators in one: BAC water reconstitution, dose conversion, and body-weight dosing with syringe unit outputs.
- Reconstitution CalculatorCalculate exactly how many units to draw on your syringe. Enter your vial size, bacteriostatic water volume, and desired dose.
- Dosage CalculatorFind evidence-based dosing ranges for any peptide. Adjust for body weight, experience level, and administration route.
Frequently Asked Questions
Why is pramlintide not more widely used despite being FDA-approved?
Several factors limit pramlintide adoption: it requires 2–3 additional daily injections on top of insulin, the mandatory 50% insulin dose reduction at initiation is complex to manage, nausea rates are high initially, and GLP-1 receptor agonists offer greater HbA1c reduction and weight loss with more convenient dosing (once-weekly). The drug has never achieved blockbuster status, with peak sales under $100 million annually.
What is the connection between pramlintide and CagriSema?
Pramlintide validated the amylin pathway for diabetes and weight management, proving that amylin analogs reduce appetite, slow gastric emptying, and improve glucose control. CagriSema builds on this by using cagrilintide, a next-generation amylin analog engineered for once-weekly dosing (versus pramlintide's 2–3× daily). CagriSema combines cagrilintide with semaglutide for dual-pathway weight loss, representing the evolution of amylin-based therapy.
Can pramlintide be mixed with insulin in the same syringe?
No. Pramlintide must not be mixed with any insulin formulation because the pH difference (pramlintide pH 4.0 vs insulin pH 7.0–7.4) causes precipitation and inactivation. They must be administered as separate injections at separate injection sites. This requirement for separate injections is one factor limiting pramlintide's clinical adoption.
Does pramlintide help with weight loss in people without diabetes?
Pramlintide has been studied for obesity in non-diabetic populations. Phase 2 trials showed 3–4% weight loss over 16 weeks, but AstraZeneca discontinued obesity-focused development because the effect was modest compared to emerging GLP-1 RAs and the thrice-daily injection schedule was impractical. However, the amylin pathway remains a validated target — cagrilintide (once-weekly amylin analog) is in phase 3 trials for obesity as part of CagriSema.
What is amylin and why is it important in diabetes?
Amylin (islet amyloid polypeptide) is a 37-amino-acid peptide hormone produced by pancreatic beta cells and co-secreted with insulin in a 1:100 ratio. In healthy individuals, amylin regulates postprandial glucose by slowing gastric emptying, suppressing glucagon, and promoting satiety. In type 1 diabetes, amylin is completely absent (beta cells are destroyed). In type 2 diabetes, amylin secretion is impaired. This deficiency contributes to postprandial hyperglycemia and overeating. Pramlintide replaces this missing hormone.
References
Latest Research
Last updated: 2026-02-19